TYROSINE KINASE INHIBITORS
Tukysa is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with advanced inoperable or metastatic HER2+ breast cancer. Tukysa may be also referred to by its drug name, tucatinib. Tukysa may be prescribed after other treatments have failed. It is prescribed in combination with Herceptin (trastuzumab) and Xeloda (capecitabine).
Tukysa is a tyrosine kinase inhibitor. Tukysa is believed to work by blocking cancer cells from growing and spreading
How do I take it?
Tukysa is taken as an oral pill taken twice per day.
Tukysa comes in the form of a 50mg or 150mg tablet.
The FDA-approved label for Tukysa lists common side effects including diarrhea, rash, nausea, fatigue, vomiting, mouth sores, decreased appetite, stomach pain, headache, low red blood cell count, and rash.
Rare but serious side effects listed for Tukysa include severe diarrhea and liver problems.
For more details about this treatment, visit:
Tukysa — Seagen
Tukysa — RxList